As per the American Skin Association, Melanoma is a life threatening malignant tumor that originates in cells called melanocytes, which are pigment-producing cells. The majority of melanomas are black or brown. However, some melanomas are skin-colored, pink, red, purple, blue or white. Melanoma begins on the skin where it is easy to see and treat. However, it can grow into the skin, reaching the blood vessels and lymphatics, and can spread within the body to various organs when it can be fatal. If it is recognized and treated early, chances of recovery are very good. But if it is not found early, it can grow deeper into the skin, and spread to other parts of the body. Once melanoma spreads beyond the skin to other parts of the body, it becomes hard to treat and can be fatal.
As per the Melanoma Research Foundation, the term malignant melanoma, or Stage IV melanoma, is used when melanoma cells of any kind (cutaneous, mucosal or ocular) spread through the lymph nodes to distant sites in the body and to the body’s organs. The liver, lungs, bones, and brain are often affected by these metastases. The causes for melanoma include high freckle density or tendency to develop freckles after sun exposure, high number of moles, having an organ transplant, etc. Melanoma signs and symptoms may include fatigue, swollen or painful lymph nodes, bone pain, headaches, seizures, and swelling of the liver.
Get FREE sample copy at:
The Melanoma market report also covers emerging drugs, current treatment practices, Melanoma market share of the individual therapies, current and forecasted Melanoma Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Melanoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Melanoma Market Key Facts
Melanoma is reported as the 19th most common cancer worldwide, with estimated age-standardized incidence rates of 2.8–3.1 per 100,000. Also, Only 20-30% of melanomas are found in existing moles and 70–80% arise on normal-looking skin.
As per the Skin Cancer Foundation, in 2013, an estimated 9,480 persons died from malignant melanoma in the United States, nearly two-third were men. Almost 60% of melanoma deaths occur in white men aged 50 years and older.
According to the Melanoma Research Foundation: In 2020, over 196,000 Americans are expected to be diagnosed with melanoma. Of these, more than 100,000 will be diagnosed with invasive (Stage I, II, III or IV) melanoma and nearly 96,000 will be diagnosed with melanoma in situ (Stage 0).
Key Benefits of Melanoma Market Report
Melanoma market report provides an in-depth analysis of Melanoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Melanoma market report will help in developing business strategies by understanding the Melanoma Market trends & developments, key players and future market competition that will shape and drive the Melanoma market in the upcoming years.
The Melanoma market report covers Melanoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Melanoma market market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
TheMelanoma market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Melanoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Melanoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Melanoma epidemiology section covers insights about historical and current Melanoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Melanoma Drugs Uptake and Key Market Players
The Melanoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Melanoma market or expected to get launched in the market during the study period. The analysis covers Melanoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Melanoma market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world. The launch of several emerging therapies is expected during the forecast period of 2020-2030. The pipeline of Melanoma is quite robust with several products available in the developmental stage. Some of the key players in the Melanoma market includes:
Spring Bank Pharmaceuticals
Chung Mei Biopharma Co. Ltd.
And many others.
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Melanoma Competitive Intelligence Analysis
4. Melanoma Market Overview at a Glance
5. Melanoma Disease Background and Overview
6. Melanoma Patient Journey
7. Melanoma Epidemiology and Patient Population
8. Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Melanoma Unmet Needs
10. Key Endpoints of Melanoma Treatment
11. Melanoma Marketed Products
12. Melanoma Emerging Therapies
13. Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Melanoma Market Outlook (7 major markets)
16. Melanoma Access and Reimbursement Overview
17. KOL Views on the Melanoma Market.
18. Melanoma Market Drivers
19. Melanoma Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Melanoma Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Melanoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Melanoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Melanoma market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States